Clinical Trial: NCT05286294
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Oslo University Hospital |
| Information Provided By: | Oslo University Hospital |
| Last Update Posted: | 2025-07-03 |
Study Overview
Brief Summary
This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as donors.
Official Title
MITRIC: Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clincal Responders
Conditions
Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, MSI-High, Clear Cell Renal Cell Carcinoma, Non-small Cell Lung Cancer
Intervention / Treatment
- Biological: Fecal Microbiota Transplant (FMT)
Other Study ID Numbers
- MITRIC
Start Date (Actual)
2022-06-28
Primary Completion Date (Estimated)
2034-03-31
Study Completion Date (Estimated)
2034-12-31
Enrollment (Estimated)
20
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Oslo University Hospital |
| Information Provided By: | Oslo University Hospital |
| Last Update Posted: | 2025-07-03 |
Study Overview
Brief Summary
This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as donors.
Official Title
MITRIC: Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clincal Responders
Conditions
Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, MSI-High, Clear Cell Renal Cell Carcinoma, Non-small Cell Lung Cancer
Intervention / Treatment
- Biological: Fecal Microbiota Transplant (FMT)
Other Study ID Numbers
- MITRIC
Start Date (Actual)
2022-06-28
Primary Completion Date (Estimated)
2034-03-31
Study Completion Date (Estimated)
2034-12-31
Enrollment (Estimated)
20
Study Type
Interventional
Phase
Phase 2